
Saturday, Nov. 9, 2024 | 12:30–1:30 p.m. | Room 320 A
Harnessing spatial multi-omics powered by spatial computing to unravel the complexities of the tumor microenvironment
Spatial intratumor heterogeneity in the tumor microenvironment is widely acknowledged as driving therapeutic response and providing fuel for drug resistance to immuno-oncology therapies. We present an unbiased and explainable AI-driven spatial multi-omics platform, SpaceIQ™, that improves our
understanding of the immunological responses to drugs in the TME and enables the development of spatial prognostic/predictive biomarkers that are key to designing precision medicine treatments. The SpaceIQ platform employs an advanced probabilistic framework to analyze spatial multi-omics data, to identify functionally relevant transition cell states, discover heterogeneous microdomains linked to disease progression, and elucidate intricate pathway interactions and signaling networks, including mechanisms of action. The SpaceIQ approach is pivotal in deciphering tumor dynamics from initiation to resistance, and discovering robust spatial biomarkers for predicting therapeutic responses.
This session will dive into multiple use cases of SpaceIQ platform utilized for various immunotherapy studies among researchers worldwide, which will be followed by a Panel Q&A session.
Presenters/panelists:
Dusty Majumdar, PhD, CEO, PredxBio
Arutha Kulasinghe, PhD, Lead Clinical-oMx Lab, Univ. of Queensland
Travis Hollman, MD, PhD, Head of Translational Pathology, Bristol Myers Squibb
Michael Surace, PhD, Director Translational Medicine, AstraZeneca
Chakra Chennubhotla, PhD, Chief of AI and Co-founder, PredxBio